ACT has been the validity check for the predictive value of the mouse model of CMV infection, disease, and CD8+ T-cell immunotherapy in the immunocompromised host, specifically also in HCT recipients under conditions of transient immunodeficiency during ongoing hematopoietic reconstitution [reviewed in (7–9)]. The gene discussed is CD8A; the disease is cytomegalovirus infection.